US equities |
SPCX $167.60 ▲+5.44% NVDA $237.23 ▲+1.40% MU $1,065.30 ▼-0.89% TSLA $377.94 ▲+1.98% MSFT $525.41 ▲+1.52% SNDK $1,708.73 ▼-0.65% INTC $116.97 ▼-1.98% META $743.94 ▲+2.18%
FinancialContent

Wave Life Sciences, Inc. - Common Stock (NQ:WVE)

3.810 +0.030 (+0.79%)
Delayed Quote Updated: 1:05 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Wave Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
What's going on in today's session ↗
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Wave Life Sciences Stock Rockets 120% After Obesity Drug Shows Deep Fat Reduction, Muscle Gain — Traders See A ‘Blockbuster' Candidate ↗
Via Stocktwits
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
News headline image
Wondering what's happening in today's pre-market session? ↗
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
Peering Into WAVE Life Sciences's Recent Short Interest ↗
 
Via Benzinga
Wave Life Sciences Tumbled 19% Today, But Not Everyone’s Disappointed – Find Out Why ↗
Via Stocktwits
News headline image
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an... 
Via MarketMinute
News headline image
These Analysts Revise Their Forecasts On Wave Life Sciences Following Q3 Results ↗
 
Via Benzinga
News headline image
Wave Life Sciences (WVE) Earnings Transcript ↗
Wave Life Sciences (WVE) Earnings Transcript 
Via The Motley Fool
News headline image
Wave Life Sciences Ltd (NASDAQ:WVE) Reports Q3 2025 Earnings Miss, Stock Falls ↗
Wave Life Sciences reported mixed Q3 2025 results, missing on revenue and EPS. Despite the financial miss, the biotech highlighted strong clinical progress for its obesity and AATD programs. 
Via Chartmill
Topics Earnings
News headline image
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
A Look Ahead: WAVE Life Sciences's Earnings Forecast ↗
 
Via Benzinga
News headline image
Wave Life Sciences to Present at Upcoming Investor Conferences
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Deep Dive Into WAVE Life Sciences Stock: Analyst Perspectives (6 Ratings) ↗
 
Via Benzinga
News headline image
Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Top movers analysis one hour before the close of the markets on 2025-09-03: top gainers and losers in today's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Forecasting The Future: 7 Analyst Projections For WAVE Life Sciences ↗
 
Via Benzinga
News headline image
Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday? ↗
Wave Life Sciences shares early WVE-006 trial results in alpha-1 antitrypsin deficiency, reporting durable protein production and favorable safety. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Falls Over 2%; Campbell's Earnings Top Estimates ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >